PART I . Overview We are a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need. We were founded on the innovation ofour novel Drug Response Predictor (DRP) platform. TheDRP technology is designed to define the gene expression signatures in cancer cells that predict the cancer cells sensitivity to a specific cancer therapeutic. Once defined, the DRP gene expression signature can then be assessed i...
Q2 FY2026 — expected 2026-09-19
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | ALLR | discussed_in_filing Cybersecurity | |
| topic_mention | ALLR | discussed_in_filing Trusted Computing | |
| topic_mention | ALLR | discussed_in_filing Blockchain & Crypto | |
| topic_mention | ALLR | discussed_in_filing Semiconductor | |
| topic_mention | ALLR | discussed_in_filing Capital Expenditure | |
| topic_mention | ALLR | discussed_in_filing Regulation | |
| topic_mention | ALLR | discussed_in_filing Healthcare & Bio | |
| topic_mention | ALLR | discussed_in_filing Platform & Ecosystem | |
| topic_mention | ALLR | discussed_in_filing Sovereign & Government | |
| topic_mention | ALLR | discussed_in_filing Cybersecurity | |
| topic_mention | ALLR | discussed_in_filing Trusted Computing | |
| topic_mention | ALLR | discussed_in_filing Blockchain & Crypto | |
| topic_mention | ALLR | discussed_in_filing Semiconductor | |
| topic_mention | ALLR | discussed_in_filing Capital Expenditure | |
| topic_mention | ALLR | discussed_in_filing Regulation | |
| topic_mention | ALLR | discussed_in_filing Healthcare & Bio | |
| topic_mention | ALLR | discussed_in_filing Platform & Ecosystem | |
| topic_mention | ALLR | discussed_in_filing Sovereign & Government | |
| topic_mention | ALLR | discussed_in_filing Cybersecurity | |
| topic_mention | ALLR | discussed_in_filing Trusted Computing |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001437749-26-010310 | EDGAR | 94K words |
| 2025-03-31 | 2024-12-31 | 0001437749-25-010198 | EDGAR | — |
| 2024-03-08 | 2023-12-31 | 0001213900-24-020864 | EDGAR | — |
| 2023-03-13 | 2022-12-31 | 0001213900-23-019295 | EDGAR | — |
| 2022-05-17 | 2021-12-31 | 0001213900-22-027311 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001437749-25-035003 | EDGAR | 18K words |
| 2025-08-15 | 2025-06-30 | 0001437749-25-027146 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0001437749-25-015780 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001437749-24-035314 | EDGAR | — |
| 2024-08-05 | 2024-06-30 | 0001213900-24-065252 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001213900-24-042997 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001213900-23-086382 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001213900-23-066893 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001213900-23-038609 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001213900-22-072355 | EDGAR | — |
| 2022-10-07 | 2022-06-30 | 0001213900-22-062840 | EDGAR | — |
| 2022-05-27 | 2022-03-31 | 0001213900-22-030179 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-01 | 0001213900-26-038061 | EDGAR | 4K words |
| 2026-03-09 | 0001213900-26-024952 | EDGAR | — |
| 2026-03-06 | 0001213900-26-024339 | EDGAR | — |
| 2026-02-19 | 0001213900-26-018161 | EDGAR | — |
| 2026-02-04 | 0001213900-26-011826 | EDGAR | — |
| 2026-01-29 | 0001213900-26-009157 | EDGAR | — |
| 2025-12-23 | 0001213900-25-124935 | EDGAR | — |
| 2025-12-08 | 0001213900-25-118989 | EDGAR | — |
| 2025-09-24 | 0001213900-25-090872 | EDGAR | — |
| 2025-09-22 | 0001213900-25-090197 | EDGAR | — |
211 total filings indexed. 184 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001860657 |
| Ticker | ALLR |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report